Kriya Therapeutics is an American gene therapy developer focused on targeting serious chronic diseases affecting millions of patients, aiming to expand the therapeutic field of gene therapy beyond rare monogenic diseases. It enables the rational design of one-off gene therapies for the durable expression of therapeutic proteins in suitable human tissues by gaining a deep understanding of the underlying biological disease. Recently completed a $270 million Series C financing, which will be used to advance its R&D pipeline and further expand its engineering, manufacturing and computing platforms.
This article is reproduced from: https://www.itjuzi.com/investevent/13221433
This site is for inclusion only, and the copyright belongs to the original author.